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Human herpesvirus 6 (HHV-6) is a lymphotropic herpesvirus, and in vitro, HHV-6 can productively infect
many of the same cell types as can human immunodeficiency virus (HIV). Coinfection by both viruses in vitro
can lead to both activation of the HIV promoter and acceleration of cytopathic effects. We have previously
demonstrated that a large, 22.25-kb cloned HHV-6 fragment, pZVB70, can trans activate HIV promoter
expression in vitro. In this study, we show that the pZVB70 fragment can trans activate the HIV promoter in
human T-cell lines as well as in the monkey kidney cell line CV-1. The pZVB70 insert was digested with various
restriction enzymes, and individual fragments were transfected into cells to test for their ability to trans activate
the HIV promoter. By this method, we have identified a 1.8-kb subfragment, B701, that is involved in trans
activation. Sequence analyses show that B701 potentially encodes a 143-amino-acidprotein. This protein shares
no homology with other herpesvirus proteins, such as ICPO and ICP4, that have been shown to trans activate
the HIV promoter. However, it shows weak sequence homology with the gene products encoded by the
cytomegalovirus early US22 gene family, suggesting that the putative B701 protein may be an HHV-6 early
regulatory protein. The 143-amino-acidcoding sequence of B701 was cloned by polymerase chain reaction, and
transfection of this construct into cells activated HIV promoter expression. The target site on the HIV promoter
for the putative B701 protein is mapped to the NF-KBbinding site. Our results suggest that the putative B701
protein may function by directly binding to the NF-KB site or may involve cellular factors, such as NF-KB,
either directly or indirectly.

Human immunodeficiency virus (HIV) is the etiologic
agent for AIDS. Infection by HIV can lead to either acute or
chronic infections, and activation signals are necessary to
establish a productive infection (8). Latent infection can
persist for years after the initial HIV infection, which can be
stimulated into acute phase by various cofactors (3). These
cofactors probably play a very important role in the pathogenesis of HIV infection and in the clinical manifestation of
AIDS. These cofactors could be of nonviral origin, such as
lymphokines (9), mitogens, or antigens (12, 33). In addition,
exogenous viral infection, such as by herpes simplex virus
(HSV) (22, 23), adenovirus (28), and hepatitis B virus (31),
have all been demonstrated to stimulate HIV replication in
vitro. It has also been shown that viral infections can lead to
the activation of HIV long terminal repeat (LTR)-directed
viral gene expression (10, 22, 32). The mechanism of activation is not completely clear, but it may involve viral gene
products, such as the immediate-early gene products of
HSV-1 (1) and cytomegalovirus (6). It is possible that these
viral gene products interact directly with the HIV LTR, or
indirectly via cellular factors such as NF-KB, in the trans
activation of HIV (10).
Among the herpesviruses that have been shown to trans
activate HIV expression, the newly identified Human herpesvirus 6 (HHV-6) seems to be most interesting. H H V d
has been isolated from AIDS patients (30, 3 9 , from patients
with lymphoproliferative disorders (30), and from children
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with exanthem subitum (34). HHV-6 infection among humans is very common, and most individuals are seropositive
for HHV-6 (15). In vitro, HHV-6 can productively infect
many of the same cell types as can HIV, particularly CD4+
human T cells, and coinfection of T cells with HIV and
HHV-6 leads to accelerated cytopathic effects (20). Recently, it has been shown that infection of CD8+ cells by
HHV-6 leads to surface expression of the CD4 molecule,
thus rendering these cells susceptible to HIV infection (21).
In contrast, other recent studies demonstrated that coinfection of peripheral blood mononuclear cells with HHV-6 and
HIV suppressed HIV replication (4, 18). The differences
between these studies may be due to the nature of the cells
that were infected, dosage of virus used, and the time of
infection. Therefore, it is important to isolate the specific
H H V d genes that may be involved in either activation or
suppression of HIV.
We have demonstrated previously that in vitro infection
with H H V d strains GS and 2-29 can activate HIV LTR
expression in human T-cell lines (13) and in a heterogeneous
population of antigen-specific primary human T lymphocytes
(14). Activation of the HIV LTR by HHV-6 in normal human
T lymphocytes potentially reflects an in vivo situation,
where there may be additive effects on trans activation by
H H V d and stimulation with specific antigen. Taken together, these results suggest that HHV-6 can potentially play
an important role in vivo as a cofactor in HIV infection and
development of AIDS.
To gain further insight into the mechanism of HHV-6 trans
activation of the HIV LTR, it is important to identify the
HHV-6 gene(s) that is involved. The genome of HHV-6 is
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about 170 kb in size, and very little is known about the
identities and functions of its gene products (16). We have
previously demonstrated that a 22.25-kb H H V d (GS) gene
segment (pZVB70) can trans activate the HIV LTR after
cotransfection into human T-cell lines (14). Here we report
the identification and characterization of a 1.8-kb gene
segment from the 22.25-kb pZVB70 fragment that can trans
activate the HIV LTR. Sequence analyses show that the
putative trans-acting protein is 143 amino acids in size and
shares no homology with other herpesvirus gene products
shown to trans activate the HIV LTR.
MATERIALS AND METHODS
Cell l i e s . The human T-cell line HSB-2 (ATCC CCL
120.1) and the African green monkey kidney cell line CV-1
(ATCC CCL 70) were used. T cells were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum,
while CV-1 cells were maintained in Dulbecco modified
Eagle medium with 10% fetal calf serum.
DNA and plasmids. Construction of various HIV-chloramphenicol acetyltransferase (CAT) plasmids was previously
described in detail (17). Briefly, the HIV-CAT construct
contains both the 3' untranslated regions and the repeat
sequences of the HIV LTR ligated to the CAT gene. The
-29 CAT plasmid was constructed by deleting all regulatory
elements on the HIV LTR except for the TATA box and the
TAR region. The -57 CAT plasmid was kindly provided by
Joseph Sodroski (Harvard Medical School, Boston, Mass.)
(29). The -147 CAT plasmid was constructed by deleting a
fragment of the HIV LTR at the AvaI site as described
elsewhere (12). The HIV LTR plasmid containing the mutated NF-KB site was kindly provided by Gary Nabel (24).
Construction of HHV-6 pZVB70 and pZVB9 plasmids containing BamHI fragments of the HHV-6 genome was described previously (14).
Transfections. HSB-2 cells were transfected by the DEAEdextran method (2). Briefly, 1 pg of DNA, suspended in 700
pg of DEAE-dextran per ml, was added to HSB-2 cells.
Cells were then incubated for 2 h at 37°C. The cells were
then treated with dimethyl sulfoxide (1%) for exactly 90 s.
After being washed with RPMI 1640 without serum, the cells
were placed in fresh RPMI 1640 medium containing 10%
fetal calf serum. Two days later, the transfected cells were
harvested, washed twice with phosphate-buffered saline
(PBS), and then used for CAT assays.
CV-1 cells were transfected by using standard calcium
phosphate precipitation procedures (11). Briefly, 0.5 x lo6 to
1 x lo6 cells were incubated with 2 pg of plasmid DNA
suspended in calcium phosphate for 8 h and then treated with
15% glycerol for 3 min. Cells were then washed with PBS
and cultured in fresh medium. After 2 days, transfected cells
were harvested for CAT assays.
CAT assays. CAT assays were performed by using
r3H]acetyl coenzyme A ([3H]acetyl-CoA). Harvested cells
were resuspended in 100 p1 of sonication buffer (0.25 M
Tris-HC1, pH 7.8). Cellular extracts were prepared by
freeze-thawing once, sonicating for 1 min, and briefly centrifuging to pellet cell debris. HSB-2 cell lysates were used
for CAT assay directly, whereas CV-1 cell lysates were heat
treated at 65°C for 5 min before CAT analysis. Protein
concentrations for each sample were determined by the BCA
protein assay (Pierce Chemical Co.). All samples were
corrected for protein concentration variations before use in
CAT assays. h-ocedures for the CAT assay using [3H]acetylCoA were previously described (25). Briefly, 50 p1 of cell

1565

lysate was mixed with 200 p1 of reaction mixture (130 p1 of
Tris-HCI [pH 7.8],50 p1 of 50 mM chloramphenicol, 1pCi of
[3Hlacetyl-Co~,19 p1 of 4 mM acetyl-CoA). Samples were
then overlaid with organic scintillation fluid and incubated at
37°C; counts were taken at 0, 1, 2, 3, 4, and 5 h after
initiation of the assay. Units of CAT activity for each lysate
were calculated by extrapolation according to a standard
curve established with known CAT enzymatic activities.
DNA sequencing and analysis. DNA sequence analyses
were performed by the Sequenase (U.S. Biochemical Corp.,
Cleveland, Ohio) method. Sequence data were analyzed by
using the SAP program (Universal Biotechnology, Inc.,
Rockville, Md.) and by the IBI-Pustell sequence analysis
program. Amino acid homology analysis was conducted by
using the FASTA program developed by Lipman and Pearson (19).
Nucleotide sequence accession number. The sequence data
presented in this report have been submitted to the GenBank
and EMBL data bases under accession number M81789.
RESULTS
HHVd (GS) genomic fragment (pZVB70) can trans activate
the HIV LTR in CV-1 cells. We have demonstrated previously that the HIV LTR can be trans activated by HHV-6
infection in human T-cell lines and in primary human T cells.
Furthermore, the 22.25-kb (pZVB70) HHV-6 genomic segment was shown to trans activate the HIV LTR when
cotransfected into human T cells (14). To determine whether
HHV-6 trans activation of the HIV LTR is cell type specific,
similar transfection studies were carried out in CV-1 cells.
These cells were chosen since various studies, including our
own, have shown that CV-1 cells can be consistently transfected with the plasmid containing the HIV LTR and provide
a good system with which to study trans activation of the
HIV LTR by various cofactors (27). CV-1 cells were cotransfected with HIV-CAT and pZVB70 DNA by the calcium phosphate precipitation method. At 48 h after transfection, cells were harvested and CAT activity was measured.
All CAT assays were done with [3H]acetyl-CoA because this
method is quantitative, reproducible, and convenient (25).
Assays were carried out for 5 h, and CAT activities were
measured hourly (Fig. 1). Increases in CAT activity were
calculated by using a standard curve of known units of CAT
enzymatic activities. Cotransfection of HIV-CAT with
pZVB70 resulted in a more than 10-fold increase in CAT
activity, and the trans activation was very consistent. For a
negative control, other cloned HHV-6 gene segments were
cotransfected into CV-1 cells along with HIV-CAT. Figure 1
shows the results of such a study using the 11.8-kb fragment
(pZVB9). No trans activation of the HIV LTR was observed
with this or other control fragments. These data demonstrate
that the trans activation of the HIV LTR by the HHV-6
DNA fragment pZVB70 is not just T-cell specific.
A functional NF-KBenhancer element is necessary for Pans
activation of the HIV LTR by pZVB70 in CV-1 cells. We have
previously demonstrated that trans activation of the HIV
LTR by HHV-6 (GS) and the pZVB70 fragment is dependent
on the presence of a functional NF-KB sequence, since an
NF-KB mutant promoter was not trans activated by HHV-6
(13,14). To study the effects of the enhancer element on the
HIV LTR and to determine whether trans activation of
HIV-CAT by pZVB70 in CV-1 cells also involves NF-KB,
transfection studies were carried out by using various HIV
promoter constructs (Fig. 2). Different constructs of the HIV
LTR were cotransfected along with pZVB70 into CV-1 cells
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FIG. 3. CAT activities in CV-1 cells that were transfected with
various deleted HIV-CAT constructs (as described in the legend to
Fig. 2) either in the presence or in the absence of pZVB70.

Time (hr)
FIG. 1. CAT enzymatic activity in CV-1 cells. CV-1 cells were
either transfected with HIV-CAT alone or cotransfected with HIVCAT and different HHV-6 plasmids. CAT activities were quantitated by using ['Hlacetyl-CoA, and incorporated radioactivities
were counted hourly. Data represent the means of at least three
independent experiments.

(Fig. 3). The promoter constructs -29 CAT and -57 CAT,
containing deleted NF-KB binding regions, lost their ability
to be trans activated by pZVB70. Within the -147 CAT
promoter construct, only the negative regulatory element
has been deleted, and this construct can still be trans
activated by pZVB70. The levels of activation were similar
to those of the intact HIV-CAT. These results thus suggest
that the target sequence may be located within the NF-KB
region. This possibility was further confirmed when an

1-1
-57

-29 CAT

+80
-147 CAT

-147

+80

I

+80

TCT

-642

Mutant

NF kB

TCT

+80

FIG. 2. Schematic diagram of various deleted HIV LTR-CAT
constructs used in transfection studies. The -29 CAT plasmid
represents a deletion of all upstream elements up to the TATA box.
The -57 CAT plasmid contains only one Spl site and the TATA
box. The -147 CAT plasmid contains the NF-KBsite, the Spl sites,
the TATA box, and the tat target region; it has lost the negative
regulatory element (NEG reg). The mutant NF-KBpromoter contains mutations in the NF-KBregions (GGG changed to TCT). Intact
HIV CAT represents the wild-type HIV LTR. RV, EcoRV.

NF-KB mutant promoter was cotransfected along with
pZVB70. This mutant promoter contains substitutions
within each of the core enhancer elements which were
implicated in binding of cellular NF-KB. These substitutions
eliminated activation of the HIV promoter by the NF-KB
protein (24). trans activation by pZVB70 in CV-1 cells was
completely abolished when the NF-KBmutant promoter was
used. These results suggest that the NF-KB sequence must
be involved in trans activation by pZVB70 in CV-1 cells,
similar to the results obtained earlier in human T cells (7, 13,
14).
Identification of a 3.8-kb fragment of pZVB70 which possesses trans activation function. The pZVB70 clone contains a
22.25-kb insert. Hence, it is necessary to further identify and
characterize the specific gene(s) involved in trans activation.
Various restriction enzymes were used to cut the pZVB70
DNA. The digested DNA were then transfected, along with
HIV-CAT, into CV-1 cells and the human T-cell line HSB-2
to determine whether they have retained their trans-activating functions. Most restriction enzymes used eliminated the
trans-activation function of pZVB70. However, digestion
with several enzymes, such as SalI, did not affect its
activity. Digestion of the pZVB70 22.25-kb insert by Sun
gave five different smaller fragments of 1.16, 3.0, 3.8, 6.0,
and 8.2 kb in size. The SalI restriction enzyme-cut sites of
pZVB70 are shown schematically in Fig. 4A. When each
SalI fragment was purified and cotransfected individually
into CV-1 cells along with HIV-CAT to test for trans
activation, only the 3.8-kb fragment trans activated HIVCAT (Fig. 4B). The trans-activation level of the purified
3.8-kb fragment is slightly lower than that of intact pZVB70
(Fig. 4B). This difference may be due to differences in
efficiency of transfection. Nevertheless, our results indicate
that the 3.8-kb fragment contains the gene(s) responsible for
the majority of the trans-activation activities observed with
the pZVB70 fragment.
Sequence analyses of the 3.8-kb fragment. To locate the
coding regions within the 3.8-kb fragment, the entire fragment was sequenced and analyzed for putative open reading
frames (ORFs). Sequence analysis revealed three ORFs that
can encode for proteins larger than 100 amino acids in size.
These three ORFs, designated ORF-A, ORF-B, and ORF-C,
are shown in Fig. 5. ORF-A initiates at nucleotide 1032 and
terminates at nucleotide 1805; its first methionine is located
at nucleotide 1378, and it can potentially encode a protein of
143 amino acids. ORF-B initiates at nucleotide 2069 and
terminates at nucleotide 2399, and it encodes a protein of 110
amino acids. ORF-C is a large ORF (366 amino acids)
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FIG. 4. (A) Schematic diagram showing the Sall restriction sites
which mapped to the pZVB70 fragment. (B) CAT activity in CV-1
cells that were cotransfected with HIV-CAT and different SalI-cut
subfragments of pZVB70. pZVB70 represents the intact plasmid,
and the numbers indicate the size in kilobases of each pZVB70 DNA
subfragment that was cotransfected with HIV-CAT.

located on the opposite DNA strand. Its amino terminus is
located outside the 3.8-kb fragment. Therefore, it is unlikely
that ORF-C encodes a functional protein that is involved in
trans activation observed with the 3.8-kb fragment.
ORF-A is responsible for trans activation of the HIV LTR.
To determine which ORF within the SalI 3.8-kb fragment is
responsible for trans-activation activities, the 3.8-kb fragment was further characterized by restriction enzyme digestion and tested for HIV-CAT trans activation. One of the
enzymes tested, AccI, eliminated ORF-B but not ORF-A,
and the AccI-digested 3.8-kb fragment still retained transactivation ability (data not shown). Thus, ORF-A may be
responsible for the trans activation of the HIV LTR. To
further confirm these results, both the 3.8-kb fragment and
the 1.86-kb fragment containing ORF-A were subcloned and
designated p3.8 and p1.86, respectively (Fig. 6). In addition,
the ORF-A coding sequence was amplified by using the
polymerase chain reaction, subcloned downstream of the
Rous sarcoma virus (RSV) LTR, and designated pB701 (Fig.
6). These subclones, p3.8, p1.86, and pB701, were cotransfected along with HIV-CAT into both CV-1 cells and human
T cells (HSB-2) and tested for trans-activation activities. All
plasmid constructs containing ORF-A were found to be

pB701

FIG. 6. Schematic diagram showing the map of plasmid pZVB70
and its various subclones. The map of pZVB70 indicates where the
SalI-cut sites are located. p3.8, p1.86, and pB701 represents the
subclones of pZVB70. Both p3.8 and p1.86 were subcloned into
pUC plasmids. pB701 was subcloned into a plasmid containing the
Rous sarcoma virus (RSV) promoter. The stippled boxes represent
ORF-A, and the open box represents ORF-B.

active in both CV-1 cells and T cells (Fig. 7), indicating that
ORF-A may indeed be the primary gene responsible for
activation of the HIV promoter. It is of interest to note that
in CV-1 cells (Fig. 7A), pB701, which uses Rous sarcoma
virus LTR as a promoter, possesses lower trans-activating
activity than does p1.86, which uses the endogenous HHV-6
promoter. However, this difference was not significant in
HSB-2 cells. In HSB-2 cells, the cloned plasmids always
gave slightly lower trans-activation activities than did the
intact pZVB70 (Fig. 7B). It is possible that a second gene in
pZVB70 also participates in the trans activation of the HIV
LTR in HSB-2 cells. Nevertheless, these results clearly
demonstrate that ORF-A is one of the major HHV-6 gene
products that trans activates the HIV LTR in both CV-1 and
human T cells. This ORF was designated B701. Our sequence analyses show that B701 encodes a protein of 143
amino acids (Fig. 8). Two potential promoters with TATAAlike sequence are found at positions 5' of the first ATG, and
a potential polyadenylation site is found at the 3' end (Fig.
8).
trans activation of HIV LTR by B701 also involves the
NF-KB region. To further confirm that B701 functions in a
similar fashion to the HHV-6 and pZVB70 fragments in trans
activation of the HIV LTR, pB701 was cotransfected along
with either the intact HIV promoter or the mutant NF-KB
promoter in both CV-1 (Fig. 9A) and HSB-2 (Fig. 9B) cells.

FIG. 5. Analysis for potential ORFs encoded by the 3.8-kb fragment of pZVB7O. The three identified ORFs larger than 100 amino acids
are designated A, B, and C. 1, 2, and 3 represent reading frames in the first DNA strand; 4, 5, and 6 represent reading frames in the opposite
strand.
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of ORF-A (B701). Numbers above the nucleotide sequence represent nucleotide numbers; those at the right represent amino acid
numbers. The two potential TATA boxes found at the 5' end of the
coding region, the termination codon TAA, and the potential polyadenylated signal sequences are highlighted by boldface.

Time (hr)
FIG. 7. CAT assays of cells that were transfected with HIV-CAT
alone or cotransfected with various subclones of pZVB70 (Fig. 6).
(A) Transfection studies done in CV-1 cells; (B) studies done in T
cells.

As expected, trans activation was abolished when the
NF-KB mutant promoter was used. Furthermore, trans
activation of the intact HIV promoter in HSB-2 by pB701 is
higher than the trans activation obtained with HHV-6 infection (Fig. 9B). Together, these results suggest that the B701
gene of HHV-6 encodes a protein which may be responsible
for most of the trans-activating activity on the HIV promoter
by HHV-6.

of different cell types need to be carried out to further
confirm these observations.
Our transfection studies show that cloned B701 fragment
activates the HIV LTR as effectively as does the entire
22.25-kb pZVB70 fragment and that this activation is at least
as effective as, if not better than, activation by HHV-6
infection. These data suggest that B701 may indeed be the
primary HHV-6 gene responsible for activation of HIV.
Previous studies by Ensoli et al. (7) and us (13, 14) have
demonstrated that activation of HIV by HHV-6 involves the

LTRpB701

-

Intact

NF-k~

-

+

+

DISCUSSION

Activation of the HIV LTR by exogenous viral infections,
such as by herpesviruses, is apparently a complex process.
For HSV-1, at least two different immediate-early gene
products, ICPO and ICP4, have been shown to enhance the
expression of HIV LTR-CAT constructs (1). However,
these stimulatory effects on the HIV LTR by cloned genomic
HSV-1, ICPO, and ICP4 fragments varied with cell type (26),
indicating that the cellular environment plays an important
role in trans activation. Our study shows that trans activation of the HIV-LTR by the HHV-6 gene fragment B701 in a
nonlymphoid cell line (CV-1) was as effective as that observed in a human T-cell line (HSB-2). It is likely that these
two cell lines involve similar cellular factors, such as NF-KB,
in mediating the trans activation. Studies using a larger panel

LTR"
GS
pB701

Intact

- + - - +

NF-k~

- + -

-

-

FIG. 9. Transfection studies done in CV-1 cells (A) or T cells (B)
with either intact HIV-CAT or mutant NF-KB CAT. Cells were
transfected with HIV-CAT alone, cotransfected with HIV-CAT and
pB701, or infected with HHV-6 (GS). Shown are counts obtained at
5 h after initiation of the assay.
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FIG. 10. Amino acid homology between the HHV-6 B701 ORF
and the human cytomegalovirus (HCMV) US22 gene product.
Amino acid comparison (ktup = 1) was performed by using the
FASTA program of Lipman and Pearson (19). Identical amino acids
are marked by two dots, and conservative changes are marked by
single dot.

NF-KB sites located in the HIV LTR. We have now demonstrated that trans activation of the HIV LTR by the cloned
B701 gene also involves NF-KB target sites. The HIV LTR
construct, with specific mutations in the NF-KB binding
sites, completely lost its ability to be activated by B701. This
finding is similar to results obtained with HHV-6 infection.
This result further supports the theory that B701 may indeed
be the major HHV-6 trans-activating gene segment. Involvement of NF-KB in activation of the HIV LTR by HHV-6 is
much more specific than with other herpesviruses. As we
have consistently observed, a single mutation in the NF-KB
core binding sequences can completely eliminate the trans
activation of the HIV LTR by HHV-6. For other transacting herpesviruses, such as HSV-1, in addition to the
NF-KB sites, the S p l sites located on the HIV LTR also
served as target sites of trans activation by HSV-1 (22).
However, there may still be HHV-6 genes other than B701
that can trans activate the HIV LTR but may or may not
involve NF-KBas a target site. Further work is in progress to
identify and characterize these genes. Nevertheless, the
specific involvement of NF-KB in trans activation by B701
provides a useful system with which to further study the
mechanism of interaction between HIV and HHV-6.
Sequence analyses show that B701 potentially encodes a
protein of 143 amino acids. It is interesting to note that such
a small herpesvirus protein has trans-acting potential. It is
possible that the putative B701 protein is part of a larger gene
product which is generated by splicing. Thus, the HHV-6
trans-activating protein may actually be a larger protein
whose functional domain is encoded by B701. The putative
B701 protein shares no sequence homology with any other
known proteins except that there is some weak homology
with the cytomegalovirus early US22 gene family (5) (Fig.
10). In one stretch of 72 amino acids, there is 29.1% identity
between the US22 and B701 ORFs. Thus, it is likely that the
putative B701 protein may also encode an early gene product
which plays a role in the regulation of viral gene expression,
similar to the ICPO and ICP4 genes of HSV (26). Studies are
now in progress to identify and characterize the protein
encoded by the B701 fragment.
There are several possible mechanisms by which the
putative B701 protein may function in trans activation of the
HIV LTR. The B701 protein can bind directly to NF-KB
target sites on the HIV LTR and activate its expression.
Alternatively, the B701 protein can function indirectly via
cellular intermediates, such as NF-KB or similar proteins.
The B701 protein may activate expression of the genes
encoding these cellular factors or may interact directly with
these factors to enhance their activities. Thus, infection of
target cells by HHV-6 may activate or elevate activities of
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cellular factors like NF-KB,which can subsequently activate
HIV expression. It has indeed been demonstrated that
HSV-1 infection of HeLa cells induces NF-KB activities
which result in augmentation of HIV LTR expression (10). It
is also tempting to speculate that HHV-6 may activate its
own gene expression via cellular factors, such as NF-KB,
which may be required for HHV-6 transcription. However, a
DNA sequence homology search indicates that the putative
B701 protein contains no obvious DNA-binding motifs or
leucine zipper-like domains which function in protein-protein interaction. Again, the exact mechanism(s) of B701
protein action in regulation of HHV-6 or HIV gene expression needs to be elucidated.
The clinical significance of HHV-6 infection alone, or
HHV-6 and HIV coinfection, remains to be determined. It is
clear that both viruses can infect the same CD4+ target T
cells and that coinfection augments HIV expression and
cytopathic effects. The identification of an HHV-6 gene such
as B701, and deciphering of the mechanisms by which it can
activate HIV, may provide a target protein for the development of agents that can block potentiation of HIV by
HHV-6.
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